Tarsus Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 4
Founded: Irvine CA United States (2016)

Organization Overview

First Clinical Trial
2020
NCT04475432
First Marketed Drug
2023
lotilaner (xdemvy)
First NDA Approval
2023
lotilaner (xdemvy)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Tarsus Pharmaceuticals | Tarsus Pharmaceuticals, Inc. | TARSUS PHARMACEUTICALS, INC.

Active Ingredients

Marketed Drugs (1)

lotilaner (xdemvy) (2023 NDA)

Drugs in Phase 4 Trials (1)

lotilaner (xdemvy) (8 trials)

Drugs in Phase 2 Trials (1)

mesalazine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharitis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 2